SPYRE THERAPUTICS

Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23... Spyre is focused on developing next generation therapeutics for people living with IBD, including ulcerative colitis (UC) and Crohn's disease (CD)... Spyre also collects non-personally identifiable information in aggregate form to track data such as the total number of visits to our website, the number of visitors to each page of our website and the domain names of our visitors' internet service providers. We use this information, which remains in aggregate, non-personally identifiable form, to understand how our visitors use our website so that we may improve our website and the services we offer.

Also known as: Spyre, Spyre Therapeutics, Spyre Therapeutics, Inc., Spyre Theraputics, Inc.

Primary location: Waltham United States